아델릭스(ARDX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.45 (+2.07%), 시가총액 $1.50B, 52주 최저~최고 $3.55 ~ $7.99.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
아델릭스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아델릭스의 현재 주가는 $3.45 (+2.07%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아델릭스의 시가총액은 약 $1.50B입니다.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule t